Half Full Glass-I had the same thoughts, and I had some concern that the stock didn't move with the Abbott news and the "progress" report issued recently by the company-searching the archives for the company, it is at different times in years past noted to be a Texas company, a Nevada(Las Vegas) company, a California company and the toll free number evidently stayed the same, typical of canadian pink sheet companies-makes one suspicious--the Japanese group who tested recaf, evidently, were surprised and pleased with the blind study (tissue samples submitted and the company accurately id'd the various tumor cell types) which occurred two or three years ago, but if it actually happened, what happened with that quite positive event? The Goshen Hospital System in Indiana was reportedly working with the company, but no news at all from that well known cancer center-I've spoken with a company official-very accomodating and open and obviously very intelligent (and very positive sounding)-I am going to try and contact the surgical oncologist, Dr Swartzenturber, who is associated with Goshen and see what he might have to say and I'll be happy to report (although I am doubtful that he'd be as accomodating as Dr Whittenberg)..the recaf identification is almost too good to be true, but if it is, why aren't the big names beating on biocurex's door (or are they)....interesting situation here...Scouty
AI
